Horizon Pharma Announces Clinical Data on RAYOS(R) (Prednisone) Delayed-Release Tablets to Be Presented at the American College
Horizon Pharma Announces Clinical Data on RAYOS(R) (Prednisone) Delayed-Release Tablets to Be Presented at the American College of Rheumatology Annual Meeting
DEERFIELD, IL -- (Marketwired) -- 10/21/13 -- Horizon Pharma, Inc (NASDAQ: HZNP) today announced that two published abstracts of its approved treatment RAYOS(R) (prednisone) delayed-release tablets will be presented during the American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (ARHP) Annual Scientific Meeting, October 25-30, 2013 in San Diego, CA.
RAYOS Abstracts to be Presented
-- Threshold Analysis of Patient Reported Morning Stiffness Where Delayed-Release (DR) Prednisone Was Compared to, and Replaced, Immediate Release Prednisone in Rheumatoid Arthritis (RA) Patients Receiving Conventional Disease-Modifying Antirheumatic Drugs (DMARDs) Over 1 Year -- Lead Author: Frank Buttgereit, M.D., Senior Consultant and Deputy Head of the Department of Rheumatology and Clinical Immunology, Charite Hospital, Berlin -- Session: Rheumatoid Arthritis - Clinical Aspects Poster III: Outcome Measures, Socioeconomy, Screening, Biomarkers in Rheumatoid Arthritis -- Tuesday, October 29, 2013: 8:30 AM-4:00 PM -- Presentation Number: 2255 -- https://ww2.rheumatology.org/apps/MyAnnualMeeting/Abstract/32990 -- Switching From Immediate Release (IR) Prednisone to Delayed Release (DR) Prednisone Improves Patient Reported Outcomes In Rheumatoid Arthritis (RA) Patients On Conventional Disease-Modifying Antirheumatic Drugs (DMARDs) -- Lead Author: Rieke Alten, M.D., Chief of the Internal Medicine Division, Schlosspark Clinic, Berlin -- Session: Rheumatoid Arthritis - Clinical Aspects Poster III: Outcome Measures, Socioeconomy, Screening, Biomarkers in Rheumatoid Arthritis -- Tuesday, October 29, 2013: 8:30 AM-4:00 PM -- Presentation Number: 2265 -- https://ww2.rheumatology.org/apps/MyAnnualMeeting/Abstract/34567
About RAYOS RAYOS, known as LODOTRA(R) in Europe, is a proprietary delayed-release formulation of low-dose prednisone. The pharmacokinetic profile of RAYOS is different with an approximately four-hour lag time from t hat of immediate-release prednisone formulations. In clinical trials studying use of RAYOS in RA, patients were administered RAYOS at 10 p.m. with food. The delayed-release profile of RAYOS helps to achieve therapeutic prednisone blood levels at a time point when cytokine levels start rising during the middle of the night. While the pharmacokinetic profile of RAYOS differs in terms of lag time from immediate-release prednisone, its absorption, distribution and elimination processes are comparable.
RAYOS utilizes SkyePharma's proprietary Geoclock(TM) technology.
Outside the United States, LODOTRA is approved for the treatment of moderate to severe active RA when accompanied by morning stiffness in over 30 countries. Horizon has granted commercialization rights for LODOTRA in Europe, Asia and Latin America to its distribution partner Mundipharma International Corporation Limited. Horizon has an exclusive license from SkyePharma for RAYOS.
Important Safety Information
RAYOS(R) (prednisone) delayed-release tablets
Approved uses of RAYOS RAYOS, a delayed-release form of prednisone, prevents the release of substances in the body that cause inflammation. RAYOS is approved to treat a broad range of diseases including rheumatoid arthritis (RA), polymyalgia rheumatica (PMR), psoriatic arthritis (PsA), ankylosing spondylitis (AS), asthma and chronic obstructive pulmonary disease (COPD). For a full list of RAYOS indications, please see full prescribing information at www.RAYOSrx.com.
RAYOS is contraindicated in patients who have known hypersensitivity to prednisone or to any of the excipients. Rare instances of anaphylaxis have occurred in patients receiving corticosteroids.
Important information about RAYOS Do not use RAYOS if you are allergic to prednisone.
Long-term use of RAYOS can affect how your body responds to stress. Symptoms can include weight gain, severe fatigue, weak muscles and high blood sugar.
RAYOS can weaken your immune system, making it easier for you to get an infection or worsening an infection you already have or have recently had.
RAYOS can cause high blood pressure, salt and water retention and low blood potassium.
There is an increased risk of developing holes in the stomach or intestines if you have certain stomach and intestinal disorders.
Behavior and mood changes can occur, including intense excitement or happiness, sleeplessness, mood swings, personality changes or severe depression.
Long-term use of RAYOS can cause decreases in bone density.
RAYOS can cause cataracts, eye infections and glaucoma.
Do not receive a "live" vaccine while taking RAYOS. The vaccine may not work as well during this time and may not fully protect you from disease.
Taking RAYOS during the first trimester of pregnancy can harm an unborn baby.
Long-term use of RAYOS can slow growth and development in children.
The most common side effects with RAYOS are water retention, high blood sugar, high blood pressure, unusual behavior and mood changes, increased appetite and weight gain.
Please see full prescribing information for RAYOS at www.RAYOSrx.com.
About Horizon Pharma Horizon Pharma, Inc. is a specialty pharmaceutical company that has developed and is commercializing DUEXIS and RAYOS/LODOTRA, both of which target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The Company's strategy is to develop, acquire, in-license and/or co-promote additional innovative medicines where it can execute a targeted commercial approach in specific therapeutic areas while taking advantage of its commercial strengths and the infrastructure the Company has put in place. For more information, please visit www.horizonpharma.com.
Contacts Robert J. De Vaere Executive Vice President and Chief Financial Officer firstname.lastname@example.org
Investors Kathy Galante Burns McClellan, Inc. 212-213-0006 email@example.com